MMP2 and neoplasm: PSTAG reduces the interaction of BiTE with nontumor cells and thereby improves its half-life, whereas PLGLAG, when cleaved by matrix metalloproteinase-2 (MMP2), augments the BiTE core to bind PD-L1 and CD3 in the tumor microenvironment and exerts its antitumor activity.